News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forticell Bioscience, Inc. Announces Collaboration Agreement with CJ CheilJedang, a Korean Pharmaceutical Giant to Use Fibrin MicroBeads (FMB(TM)) for Novel Umbilical Cord Blood Stem Cell Recovery


1/14/2008 9:04:38 AM

NEW YORK--(BUSINESS WIRE)--Forticell Bioscience, Inc. (OTCBB: FORB - News) announced today that it has entered into a Material Transfer and Technology Evaluation Agreement with CJ CheilJedang. (CJ), one of the largest Food and Healthcare companies in South Korea, granting CJ the exclusive right for a limited time to use it’s Fibrin MicroBeads (FMB™) technology for the extraction and expansion of mesenchymal-type stem cells (MSC) from human umbilical cord blood (UCB). Its wholly owned subsidiary, Hapto Biotech, Inc.

Read at press release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES